Action Nurexone Biologic - NRX

Nurexone Biologic Inc (NRX) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

0,58

( 5,45% )

Prix Achat

0,57

Prix Vente

0,60

Volume échangé

3 500

0,58 Fourchette du Jour 0,60

0,51 Plage de 52 semaines 1,14

Cap du marché

53,387M

Clôture Veille

0,55

Ouverture

0,59

Dernière Transaction

1000

0.58

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

$ 18 436

Actions en circulation

92 045 848

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-5,05

Bénéfice par action (BPA)

-0,08

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-6,47M

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toron... NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

nurexone.com

Siège social

Toronto, Canada

Fondé

2026

Nurexone Biologic Inc est coté dans le secteur Healthcare de la TSX Venture Exchange avec le ticker NRX. Le dernier cours de clôture d'Nurexone Biologic était de $0,55. Au cours de la dernière année, les actions de Nurexone Biologic ont été négociées dans une fourchette de prix de $ 0,51 à $ 1,14.

Nurexone Biologic compte actuellement 92 045 848 actions en circulation. La capitalisation boursière d'Nurexone Biologic est de $53,39 million. Nurexone Biologic a un ratio cours/bénéfice (ratio PE) de -5.05.

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone...

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

NurExone Announces Corporate Updates

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.03	5.45454545455	0.55	0.6	0.54	18259	0.55186768	CS
4	-0.06	-9.375	0.64	0.66	0.51	17018	0.56353657	CS
12	-0.05	-7.93650793651	0.63	0.67	0.51	16404	0.59744459	CS
26	-0.08	-12.1212121212	0.66	0.7	0.51	20022	0.6248078	CS
52	-0.1	-14.7058823529	0.68	1.14	0.51	35866	0.77885266	CS
156	0.33	132	0.25	1.19	0.185	44171	0.73099047	CS
260	-0.22	-27.5	0.8	1.19	0.1	34502	0.7160229	CS

NRX - Frequently Asked Questions (FAQ)

What is the current Nurexone Biologic Inc share price?

The current share price of Nurexone Biologic Inc is $ 0,58

How many Nurexone Biologic Inc shares are in issue?

Nurexone Biologic Inc has 92 045 848 shares in issue

What is the market cap of Nurexone Biologic Inc?

The market capitalisation of Nurexone Biologic Inc is CAD 53,39M

What is the 1 year trading range for Nurexone Biologic Inc share price?

Nurexone Biologic Inc has traded in the range of $ 0,51 to $ 1,14 during the past year

What is the PE ratio of Nurexone Biologic Inc?

The price to earnings ratio of Nurexone Biologic Inc is -5,05

What is the registered address of Nurexone Biologic Inc?

The registered address for Nurexone Biologic Inc is 1 Adelaide Street East, Toronto, Ontario, M5C 2V9

What is the Nurexone Biologic Inc website address?

The website address for Nurexone Biologic Inc is nurexone.com

Which industry sector does Nurexone Biologic Inc operate in?

Nurexone Biologic Inc operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Nurexone Biologic Inc (NRX)

Nurexone Biologic Inc (NRX) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Nurexone Biologic Inc

NRX Dernières nouvelles

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

NurExone Announces Corporate Updates

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

Meet the micro-cap biotech company reinventing regenerative medicine

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

NurExone Announces Corporate Updates

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

NRX - Frequently Asked Questions (FAQ)

NRX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités